Screening simulator for lecanemab/donanemab-class anti-amyloid monoclonal antibody therapy — clinical stage, biomarker confirmation, APOE4/ARIA risk, and MRI safety gates
Anti-amyloid monoclonal antibodies were studied — and are labeled — for a narrow slice of the Alzheimer's continuum: mild cognitive impairment (MCI) due to AD and mild AD dementia, collectively "early symptomatic" disease. Patients with moderate or severe dementia were excluded from Clarity AD and TRAILBLAZER-ALZ 2, and label indications explicitly restrict use to this early window — treating outside it has neither efficacy data nor a favorable risk/benefit profile.
Clinical staging for anti-amyloid therapy relies on a combination of instruments, not a single score:
Clinical Dementia Rating (CDR): • CDR-Global 0.5: MCI — mild memory complaints, largely preserved function • CDR-Global 1.0: mild dementia — noticeable impairment, some functional decline • CDR ≥2: moderate/severe dementia — excluded from anti-amyloid mAb trials
Mini-Mental State Examination (MMSE): • Clarity AD (lecanemab): required MMSE 22–30 • TRAILBLAZER-ALZ 2 (donanemab): required MMSE 20–28 • Lower MMSE correlates with more advanced neurodegeneration, where amyloid removal has diminishing clinical return
Objective memory impairment: • Confirmed via Wechsler Memory Scale — Logical Memory II, with education-adjusted cutoffs • Ensures enrollment reflects true amnestic MCI/AD rather than non-AD cognitive complaints
Why the window is narrow: amyloid plaque burden plateaus early in the disease course, while downstream tau pathology and neurodegeneration — not amyloid — drive further decline once dementia is established. Removing amyloid in advanced disease has not been shown to meaningfully slow a process already dominated by neuronal loss, while ARIA risk remains just as real.
Roughly half of patients referred for anti-amyloid therapy are staged out at this first gate — either too early (subjective complaints without objective impairment) or, more commonly, already past the mild-dementia cutoff by the time they reach a specialty clinic.
Clinical impression alone is not sufficient to start an anti-amyloid antibody. Both lecanemab and donanemab labels require objective confirmation of amyloid pathology — via amyloid-PET imaging or a cerebrospinal fluid (CSF) Aβ42/40 ratio (often paired with p-tau181) — before the first infusion. This single gate screens out a substantial fraction of clinically diagnosed patients whose cognitive symptoms are not, in fact, driven by amyloid.
Amyloid-PET imaging: • Radiotracer (¹⁸F-florbetapir, flutemetamol, or florbetaben) binds fibrillar amyloid-β plaques • Read as visually positive/negative, or quantified on the Centiloid scale (0 = young amyloid-negative controls, 100 = typical AD) • Centiloid >20–30 is generally considered biomarker-positive • Non-invasive, widely available at academic centers, but costly and often not reimbursed for this specific indication
CSF biomarkers: • Aβ42/40 ratio: decreases in AD as Aβ42 is sequestered into plaques rather than remaining soluble in CSF • p-tau181 (or p-tau217): rises with AD-related tangle pathology; often combined with Aβ42/40 into a ratio for higher accuracy • Requires lumbar puncture — more invasive but cheaper and more accessible than PET in many health systems • Concordance between CSF and PET positivity is high (~90%) but not perfect
Both pathways are considered interchangeable for eligibility purposes in current labeling — the requirement is documented amyloid pathology, not a specific modality.
A clinical diagnosis of "probable Alzheimer's dementia" based on history and cognitive testing alone is wrong in a meaningful minority of cases — other causes of amnestic MCI/dementia (vascular cognitive impairment, limbic-predominant TDP-43 pathology/LATE, hippocampal sclerosis, primary tauopathies) can closely mimic AD clinically but lack amyloid pathology entirely.
Treating an amyloid-negative patient with an anti-amyloid antibody exposes them to ARIA risk and infusion burden with no plausible mechanism of benefit — the biomarker gate exists precisely to prevent this. In pivotal trials, amyloid-PET or CSF screen failure was one of the largest single reasons candidates were not randomized.
APOE ε4 is the strongest common genetic risk factor for late-onset Alzheimer's disease — and, independently, the strongest predictor of ARIA (amyloid-related imaging abnormalities) once anti-amyloid antibody therapy begins. Risk scales with allele dose: noncarriers have the lowest ARIA rates, heterozygotes intermediate, and ε4/ε4 homozygotes the highest — high enough that both lecanemab and donanemab carry boxed warnings recommending genotyping and enhanced counseling before treatment.
APOE4 promotes cerebral amyloid angiopathy (CAA) — deposition of amyloid-β within the walls of cerebral blood vessels rather than only in parenchymal plaques. When anti-amyloid antibodies mobilize and clear vascular amyloid, the weakened, amyloid-laden vessel walls become more prone to leaking (producing vasogenic edema — ARIA-E) or microhemorrhage (ARIA-H).
Because APOE4 gene dose directly correlates with CAA burden, it correlates directly with ARIA incidence: • 0 alleles: lowest CAA burden, lowest ARIA rates • 1 allele: intermediate CAA burden and ARIA rates • 2 alleles (homozygous, ~2–3% of the population): highest CAA burden and by far the highest ARIA rates, including a higher share of symptomatic and severe cases
Both lecanemab and donanemab labeling recommend APOE ε4 genotyping before initiating treatment specifically so that homozygous patients — and their families — can have an informed discussion about substantially elevated ARIA risk before consenting to therapy.
ARIA-E (edema/effusion): fluid accumulation in brain parenchyma or sulci, visible as hyperintensity on FLAIR MRI sequences. Usually asymptomatic, detected only on scheduled monitoring scans; when symptomatic, presents as headache, confusion, visual disturbance, or seizure.
ARIA-H (hemorrhage): microhemorrhages or superficial siderosis, visible on gradient-echo (GRE) or susceptibility-weighted imaging (SWI). Often co-occurs with ARIA-E in higher-risk patients (especially homozygotes) since both arise from the same underlying vascular amyloid clearance process.
Most ARIA is radiographically mild and resolves over weeks to months with dose interruption; a small minority — disproportionately concentrated in APOE4 homozygotes — is severe or, rarely, fatal, particularly when compounded by anticoagulant use or macrohemorrhage.
Before the first infusion, every candidate undergoes a baseline brain MRI with gradient-echo or susceptibility-weighted sequences — the imaging tools sensitive enough to detect the microhemorrhages, siderosis, and vascular changes that predict a higher risk of severe ARIA. This is a hard safety gate: several structural and medication findings exclude or substantially caution against starting therapy regardless of amyloid status or cognitive stage.
A qualifying baseline MRI must be free of:
• More than 4 microhemorrhages (small, punctate hemosiderin deposits on GRE/SWI) • Superficial siderosis — a hemosiderin rim along the cortical surface, a hallmark of advanced cerebral amyloid angiopathy • Any prior macrohemorrhage (>1cm) or evidence of an unresolved vascular lesion • Areas of pre-existing vasogenic edema or an intracranial finding suggesting a non-AD structural cause of cognitive decline
Each of these findings signals a vascular substrate that anti-amyloid clearance could destabilize further — the same CAA-driven mechanism underlying ARIA itself, just already visible before treatment starts.
Concurrent anticoagulant therapy (warfarin, DOACs) carries a specific boxed warning for both lecanemab and donanemab: rare but serious, including fatal, intracerebral hemorrhages have been reported in patients on anticoagulants who experienced ARIA-H. This does not universally exclude anticoagulated patients, but requires a careful individualized risk discussion and closer monitoring.
Other caution flags evaluated alongside the MRI: history of seizure disorder, use of thrombolytics, and — as covered in Stage 3 — APOE4 homozygosity, which compounds hemorrhagic risk when combined with any of the above.
When ARIA is detected during treatment, management is stratified by severity: mild-to-moderate radiographic ARIA without severe symptoms often allows continued dosing with closer monitoring; more severe or symptomatic ARIA requires dose interruption and, in some cases, permanent discontinuation.
The four screening gates — clinical stage, amyloid confirmation, APOE4/ARIA risk, and MRI safety — combine into a single determination: Eligible, Caution (proceed with intensified counseling and monitoring), or Not Eligible. Patients who start treatment enter a structured serial-MRI surveillance schedule designed to catch ARIA before it becomes symptomatic, while the field continues to debate whether the resulting clinical benefit justifies the burden.
Beyond the baseline scan, labeled monitoring MRIs are performed at defined checkpoints — commonly before the 5th, 7th, and 14th infusions in the first year of biweekly or monthly dosing — since ARIA incidence peaks early in the treatment course (typically within the first 2–3 months) and then declines.
Additional unscheduled scans are obtained promptly for any new neurological symptom (headache, confusion, visual change, seizure) that could represent symptomatic ARIA. Higher-risk patients — APOE4 homozygotes, those with baseline microhemorrhages near the exclusion threshold — often receive more frequent or earlier monitoring by clinical judgment, even though this is not separately specified in labeling.
Both pivotal trials met their primary endpoints with statistical significance: lecanemab slowed decline on the CDR-Sum of Boxes by 27% relative to placebo over 18 months (Clarity AD); donanemab showed a comparable effect on the integrated ADRS/iADRS scale (TRAILBLAZER-ALZ 2), with larger effects in patients with lower baseline tau burden.
The absolute difference, however, is small — roughly a 0.45-point difference on an 18-point CDR-SB scale — and there is genuine, ongoing debate among clinicians and researchers about whether this magnitude is perceptible to patients and families in daily life, versus being a real but modest slowing that is more meaningful cumulatively over a longer horizon than any trial has yet measured.
Anti-amyloid antibody therapy is a substantial undertaking beyond the drug itself: biweekly (lecanemab) or monthly (donanemab) IV infusions, each requiring clinic time and infusion-reaction monitoring; the baseline and surveillance MRI series; the initial PET or CSF confirmation; and specialist visits to interpret each result. List prices run roughly $26,000–32,000 per year for the drug alone, before accounting for imaging, infusion-center fees, and caregiver time — a real access barrier layered on top of the clinical eligibility funnel itself.
Eligibility screening for anti-amyloid therapy is best understood as a funnel, not a single test: of patients who start with a clinical AD diagnosis, a meaningful fraction is staged out by dementia severity, another fraction by amyloid-negative biomarkers, and a further fraction by MRI safety findings — leaving a carefully selected group for whom the risk/benefit balance is judged favorable.